Understanding the pathophysiology is the key to novel therapies for canine dilated cardiomyopathy.
Elliott
J
J
Marr
C M
CM
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy / Q000503:physiopathology*; D004285:Dogs; D009490:Neurosecretory Systems / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors